Zenas BioPharma, Inc.
ZBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001953926
No open-market purchases or sales by Zenas BioPharma, Inc. insiders were filed in the last 90 days; 144 institutions reported holding it in 13F filings for Q2 2026, worth $1.55B in total; no superinvestor holds it.
13F holders, Q4 2025
Institutional positions in Zenas BioPharma, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 119
- +39 vs. Q3 2025
- Shares held
- 42.8M
- +8.00M (+23.0%) vs. Q3 2025
- Total value
- $1.55B
- +$776.2M (+100.2%) vs. Q3 2025
- New holders
- 47
- 37 more added
- Sold out
- 8
- 24 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ZBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 144 | $1.55B |
| Q1 2026 | 140 | $1.14B |
| Q4 2025 | 119 | $1.55B |
| Q3 2025 | 80 | $774.5M |
| Q2 2025 | 73 | $330.0M |
| Q1 2025 | 67 | $256.7M |
| Q4 2024 | 65 | $259.6M |
| Q3 2024 | 44 | $418.5M |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Zenas BioPharma, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rock Springs Capital Management LP | 502,077 | $18.2M | 0.94% | −78,600−13.5% | Reduced |
| Geode Capital Management, LLC | 588,393 | $21.4M | 0.00% | +118,358+25.2% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 591,991 | $21.5M | 8.31% | −187,054−24.0% | Reduced |
| ArrowMark Colorado Holdings LLC | 751,161 | $27.3M | 0.60% | −73,507−8.9% | Reduced |
| EcoR1 Capital, LLC | 789,500 | $28.7M | 1.31% | +789,500 | New |
| Vivo Capital, LLC | 853,495 | $31.0M | 2.00% | −329,765−27.9% | Reduced |
| Wellington Management Group LLP | 855,334 | $31.1M | 0.01% | −2,190−0.3% | Reduced |
| Polar Capital Holdings Plc | 1,057,609 | $38.4M | 0.18% | +1,057,609 | New |
| Royalty Pharma Sub-Manager, LLC | 1,263,150 | $45.9M | 26.77% | +1,263,150 | New |
| Novo Holdings A/S | 1,450,000 | $52.6M | 4.09% | −550,000−27.5% | Reduced |
| Vanguard Group Inc | 1,453,065 | $52.8M | 0.00% | +290,307+25.0% | Added |
| BlackRock, Inc. | 1,767,518 | $64.2M | 0.00% | +538,877+43.9% | Added |
| NVP Associates, LLC | 1,838,482 | $66.8M | 26.16% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 2,209,025 | $80.2M | 6.11% | +316,219+16.7% | Added |
| Federated Hermes, Inc. | 2,715,578 | $98.6M | 0.16% | +853,740+45.9% | Added |
| NEA Management Company, LLC | 3,523,219 | $127.9M | 6.52% | +789,500+28.9% | Added |
| Enavate Sciences GP, LLC | 3,919,159 | $142.3M | 28.08% | +157,800+4.2% | Added |
| Sr One Capital Management, LP | 5,037,854 | $182.9M | 25.90% | +126,315+2.6% | Added |
| FMR LLC | 7,704,255 | $279.7M | 0.01% | +2,883,885+59.8% | Added |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −1,562,942−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −152,025−100.0% | Sold out |
| Summit Wealth Group LLC | 0 | $0 | 0.00% | −51,356−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −38,742−100.0% | Sold out |
| Birchview Capital, LP | 0 | $0 | 0.00% | −16,500−100.0% | Sold out |
| American Century Companies Inc | 0 | $0 | 0.00% | −10,981−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −1,134−100.0% | Sold out |
| SBI Securities Co., Ltd. | 0 | $0 | 0.00% | −1−100.0% | Sold out |